Bio

Academic Appointments


Honors & Awards


  • Rathmann Fellow, E4C Medical Education Fellowship in Patient Centered Care. (July 2014 - June 2015)

Research & Scholarship

Clinical Trials


  • Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Recruiting

    The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.

    View full details

  • Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Recruiting

    The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

    View full details

  • Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock Recruiting

    To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge, versus subjects who receive standard medical care alone.

    View full details

  • Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection Recruiting

    The aim of this study is to evaluate the efficacy of the candidate Clostridium difficile (C. difficile) vaccine to prevent primary symptomatic C. difficile infection (CDI) in subjects a risk for CDI where there is a substantial unmet medical need. Primary objective: - To assess the efficacy of the C. difficile vaccine in preventing the onset of symptomatic primary CDI confirmed by polymerase chain reaction (PCR) in adult subjects aged ≥ 50 years who are at risk for CDI and have received at least 1 injection. Secondary Objectives: Efficacy: - To assess prevention of symptomatic PCR-confirmed primary CDI cases after 3 injections administered at 0, 7, and 30 days - To assess prevention of symptomatic PCR-confirmed primary CDI cases after completion of at least 2 injections. Immunogenicity: - To describe the immunogenicity to toxin A and toxin B in the subset of subjects at specific time points. Safety: - To describe the safety profile of all subjects who receive at least 1 injection.

    View full details

Teaching

Graduate and Fellowship Programs


  • Critical Care Medicine (Fellowship Program)

Stanford Medicine Resources: